Login / Signup

The Research Advances of Aptamers in Hematologic Malignancies.

Yongkang LiaoShijun XiongZaid Ur RehmanXiaoli HeHongling PengJing LiuShuming Sun
Published in: Cancers (2023)
Currently, research for hematological malignancies is very intensive, with many breakthroughs. Among them, aptamer-based targeted therapies could be counted. Aptamer is a targeting tool with many unique advantages (easy synthesis, low toxicity, easy modification, low immunogenicity, nano size, long stability, etc.), therefore many experts screened corresponding aptamers in various hematological malignancies for diagnosis and treatment. In this review, we try to summarize and provide the recent progress of aptamer research in the diagnosis and treatment of hematologic malignancies. Until now, 29 aptamer studies were reported in hematologic malignancies, of which 12 aptamers were tested in vivo and the remaining 17 aptamers were only tested in vitro. In this case, 11 aptamers were combined with chemotherapeutic drugs for the treatment of hematologic malignancies, 4 aptamers were used in combination with nanomaterials for the diagnosis and treatment of hematologic malignancies, and some studies used aptamers for the targeted transportation of siRNA and miRNA for targeted therapeutic effects. Their research provides multiple approaches to achieve more targeted goals. These findings show promising and encouraging future for both hematological malignancies basic and clinical trials research.
Keyphrases
  • cancer therapy
  • gold nanoparticles
  • nucleic acid
  • clinical trial
  • sensitive detection
  • drug delivery
  • magnetic nanoparticles
  • label free
  • quantum dots
  • case control
  • combination therapy
  • double blind